Stock Ratings / Health Care / PYXS / financials

KROS (66) SLGL (54) SIGA (72) BBOT (37) ⌘ Pro Terminal →

Pyxis Oncology Inc. (PYXS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.81 -4.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.79

Pyxis Oncology Inc. (PYXS) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $226.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PYXS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.81 (-4.23% 1D, market cap $226.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PYXS ranks #880 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PYXS compare to KROS and SLGL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 85.0%, cap $225.2M) and SLGL (Sol-Gel Technologies Ltd.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $224.8M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PYXS?

▼

Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.79 (-0.95%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PYXS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY PYXS SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 34.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.01-12.4% Next Q

Q2 (-2Q)

Grade E$1.76-4% Next Q

Q3 (-1Q)

Grade E$1.69+7.1% Next Q

Current

Grade E$1.81-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PYXS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PYXS currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.63) and Max Pain ($1.90) forces dealer call-delta covering toward $5.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PYXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PYXS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $13.9M

FY24

Rev $16.1M

FY25

Rev $13.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$13.9M	82.8%	-80%	-$79.6M	-$63.5M	-45%
FY 2024	$16.1M	97.1%	-80%	-$77.3M	-$57.9M	-45%
FY 2023	$13.9M	82.8%	-593.1%	-$73.8M	-$70.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYXS)

✓Walkthrough of PYXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PYXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.84%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.83H $1.86L $1.68C $1.81VOL 427.9K

RES: $4.99SUP: $1.60SMA50: $2.63SMA200: $2.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PYXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PYXS Butterfly Map → + Track PYXS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PYXS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PYXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PYXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYXS)

Health Care Rank #880 of 1016 ⚔️ KROS vs PYXS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PYXS vs. KROS, SLGL, SIGA, BBOT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pyxis Oncology Inc. (PYXS) ranks #880 by composite RQD confidence (29/100, grade E) and #560 by equity capitalization ($226.0M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PYXS at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PYXS ACTIVE Pyxis Oncology Inc.	E	29/100	—	82.8%	-35.0%	-4.23%	$226.0M	Benchmark Subject
KROS Keros Therapeutics Inc.	C+	66/100	—	—	85.0%	-2.82%	$225.2M	/kros-vs-pyxs →
SLGL Sol-Gel Technologies Ltd.	D+	54/100	—	—	-35.0%	-0.45%	$224.8M	/slgl-vs-pyxs →
SIGA SIGA Technologies Inc.	B	72/100	9.8x	68.6%	42.7%	-4.40%	$228.5M	/siga-vs-pyxs →
BBOT BridgeBio Oncology Therapeutics Inc.	D-	37/100	—	—	-35.0%	-2.96%	$216.5M	/bbot-vs-pyxs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782223

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pyxis Oncology Inc. (PYXS) reported GAAP revenue of $13.9M (-14.2% vs. FY2024 revenue of $16.1M ) , GAAP net income of -$79.6M, operating cash flow of -$63.5M, and free cash flow of -$63.5M (-9.7% YoY). On the balance sheet, PYXS closed FY2025 with $91.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.9M	-$79.6M	-$63.5M	-$63.5M	$91.5M	—
FY2024 (FY)	2024-12-31	$16.1M	-$77.3M	-$57.7M	-$57.9M	$157.2M	—
FY2023 (FY)	2023-12-31	$0	-$73.8M	-$70.7M	-$70.7M	—	—

3. PYXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PYXS compare to KROS and SLGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PYXS?

Where is PYXS trading relative to its 50-day, 200-day, and 52-week technical levels?

PYXS last traded at $1.81 (-4.23% on volume of 686,540 shares), positioning the stock -31.18% below its 50-day simple moving average ($2.63) and -16.20% below its 200-day simple moving average ($2.16). Across its 52-week range of $1.03 to $5.55, PYXS sits at the 17.3% percentile with a 14-day RSI of 34.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.58 to $2.04).

PYXS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Pyxis Oncology Inc. (PYXS)?

In FY 2025 (10-K), PYXS converted $13.9M of revenue into a 82.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PYXS RQD Cockpit PYXS 12M Forecast PYXS Earnings & Move PYXS Dividends & DRIP PYXS Insiders & 13F PYXS Whale Options PYXS Profit Sankey PYXS News & Why

Sector Peer Dials

Compare →

KROS C+

Keros Therapeutics Inc.

66 /100

SLGL D+

Sol-Gel Technologies Ltd.

54 /100

SIGA B

SIGA Technologies Inc.

72 /100

BBOT D-

BridgeBio Oncology Therapeutics Inc.

37 /100

NATR C+

Nature's Sunshine Products Inc.

PYXS Core Snapshot

Market Cap $226.0M

Trailing / Fwd P/E — / —

Gross Profit Margin 82.8%

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $1.57

FREE TRADER TOOLS

Own PYXS Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With PYXS → 🏆 Trade PYXS in $100K Prop Arena →

PYXS Wire

Why It Moved →

Direct Company Event Yahoo! Finance Canada • 6h ago

Pyxis Oncology, Inc. (PYXS) Stock Price, News, Quote & History

Direct Company Event Seeking Alpha • 9h ago

Pyxis Oncology: Better Runway Is Bullish For MICVO’s Remaining R&D (NASDAQ:PYXS)

Direct Company Event StockInvest.us • 12h ago

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS?

Direct Company Event TradingView • 15h ago

Price to book forward of Pyxis Oncology, Inc. – NASDAQ:PYXS

Peer / Ecosystem Wire Stock Titan • 18h ago

One cancer drug spans three presentations, from lab tests to patient study

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PYXS — Pyxis Oncology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PYXS scores 29 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows. Fundamental cash engine scores 6/20, reflecting ROIC of -35% and an FCF yield of 0%. Whale 13F flow scores 4/20, covering institutional accumulation and options positioning. Insider conviction scores 3/20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 8/20, with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 8/20, citing an Altman Z of 2.5, a Piotroski F of 3/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to weak cash generation and low scores across ownership-signal pillars. The fundamental pillar is the most direct caution: negative ROIC and zero FCF yield indicate the business is not currently converting capital into owner cash returns. The insider and whale pillars score lowest, which the rating reads as limited conviction from insiders and institutions in the source data. The balance-sheet pillar is middling rather than distressed, so solvency is a less acute concern than operating losses. Upside drivers, if any, would have to come from changes in the cash engine or in ownership conviction, neither of which the rating currently shows. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$13.9M	$-84.4M	$-79.6M	N/A	$-63.5M	$15.4M	N/A
FY 2024	$16.1M	$-89.5M	$-77.3M	N/A	$-57.9M	$19.5M	N/A
FY 2023	$0.0M	$-82.2M	$-73.8M	N/A	$-70.7M	N/A	N/A

Per the SEC financials, operating losses and negative free cash flow appear in each reported period, and revenue declined from $16.1M in FY 2024 to $13.9M in FY 2025. Per the market data, ROIC is -35% and the operating margin is -60%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity of 0.5. Cash is reported for FY 2025 and FY 2024, and debt is not available in source data for any period.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to PYXS, from sources including Yahoo! Finance Canada, Seeking Alpha, StockInvest.us, TradingView, Stock Titan, and ad-hoc-news.de. Headlines cover general market and institutional coverage, a Seeking Alpha piece titled around a better runway for remaining R&D, a Stock Titan item on a cancer drug spanning three presentations, and an ad-hoc-news.de item referencing a Wells Fargo price target of USD 19.00. The Seeking Alpha item is classified as a CATALYST and carries a GREEN light; the remaining items are classified as market wire and carry YELLOW lights. The Wells Fargo target is listed in the headline but is not corroborated by the analyst section. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so there are no graph-derived catalysts.

Open Questions

What are the company's products, pipeline stage, and revenue sources, given that the profile and business description lack detail?
What explains the decline in revenue from FY 2024 to FY 2025, and what is driving the operating losses?
Why is debt reported as N/A across all periods while the RQD rating cites a Debt/Equity of 0.5?
What is the cash runway implied by $15.4M in cash against FY 2025 negative FCF of $-63.5M?
What is the basis for the Wells Fargo USD 19.00 target referenced in the news feed, given that analyst data is absent?

PYXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pyxis Oncology Inc. (PYXS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PYXS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

Pyxis Oncology, Inc. (PYXS) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 9h ago

Pyxis Oncology: Better Runway Is Bullish For MICVO’s Remaining R&D (NASDAQ:PYXS)

Seeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 12h ago

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS?

StockInvest.us report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 15h ago

Price to book forward of Pyxis Oncology, Inc. – NASDAQ:PYXS

TradingView report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

One cancer drug spans three presentations, from lab tests to patient study

Stock Titan report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 21h ago

Pyxis Oncology stock: Wells Fargo keeps USD 19.00 target for PYXS stock

ad-hoc-news.de report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Yahoo Finance report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Seeking Alpha • 1d ago

Pyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVO

Seeking Alpha report covering Pyxis Oncology Inc. (PYXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PYXS Bull vs. Bear Conversation Board — What's Your Call at $1.81?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PYXS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.66 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PYXS (E • RQD 29/100) a Buy at $1.89?

Welcome to the PYXS (Pyxis Oncology Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.42 (-24.9%)

Spot @ $1.89

Pump the brakes on PYXS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PYXS, but look at what you are paying: current EV/EBITDA multiples with 82.8% gross margins. Unless Pyxis Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.32 (+22.8%)

Spot @ $1.89

PYXS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PYXS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.89 (52-wk range $1.77 - $2.18), any beat on forward guidance forces shorts and underweight funds to chase.